The public conversation about psilocybin microdosing and macrodosing often treats them as points on the same spectrum. Neurobiologically and clinically, they are closer to different interventions with different evidence bases, different indications, and different risks.
What a Microdose Is (and Isn't)
A microdose is typically defined as roughly 5-10% of a full psychoactive dose — sub-perceptual, with the intent of producing subtle cognitive or affective shifts without the classical psychedelic experience. Common protocols involve dosing every third day. The publicly-reported subjective benefits — mood, focus, creativity — are consistent, but the placebo-controlled trial evidence is meaningfully less consistent (Szigeti et al., 2021; Kaertner et al., 2020). This does not mean microdosing does nothing; it means the effect size when tested against placebo is smaller than uncontrolled self-report suggests.
What a Macrodose Actually Does Neurobiologically
A full macrodose — typically 20-30+ mg dried psilocybin equivalent — produces the classical psychedelic experience: 5-HT2A engagement, default-mode-network disruption, potential mystical-type experience, and a documented downstream window of neuroplasticity. This is the dose used in the treatment-resistant depression trials (Carhart-Harris et al., 2021; Davis et al., 2021), the addiction trials, and the end-of-life distress work. The therapeutic effect appears to be driven not by the receptor engagement per se but by the acute experience combined with integration.
The Evidence Base: Not Interchangeable
Macrodose psilocybin-assisted therapy for major depression, treatment-resistant depression, alcohol use disorder, tobacco cessation, and end-of-life anxiety has generated multiple positive RCTs with meaningful effect sizes. Microdosing has generated positive naturalistic and observational studies but placebo-controlled work has been more mixed. The clinical implication is that macrodose protocols are on stronger evidentiary ground for defined psychiatric indications; microdosing is best understood as a lifestyle intervention with subjective benefit for many users and inconsistent measurable benefit in controlled settings.
How Sanctuary Tulum Uses Each
Our program is macrodose-based. We do not run microdose protocols as our primary intervention because our guests typically arrive with serious pathology — treatment-resistant depression, PTSD, addiction, benzodiazepine dependence, chronic anxiety — that the evidence supports treating with full-dose sessions embedded in a residential protocol. Microdosing may have a place in continued outpatient integration for some guests, guided by their prescribing physicians. See our full psilocybin therapy program and trial evidence review.
Risks Specific to Each
Microdose risks include valvulopathy concerns with chronic 5-HT2B agonism in high-frequency long-duration protocols — a theoretical concern flagged in the pharmacology literature that deserves more research. Macrodose risks include acute psychological distress, HPPD (rare), and destabilization in guests with undiagnosed psychotic-spectrum vulnerability. Screening and setting reduce macrodose risk substantially; the risks of unsupervised chronic microdosing are less well-characterized precisely because the population is dispersed and self-managed. Explore our psilocybin vs SSRIs comparison.
